Table 1 Baseline characteristics and outcomes of patients attending an HIV clinic in Johannesburg, South Africa, stratified by missed visit status in the first six months of ART (n = 4476)
| Â | Missed visit status (Medical or ARV) | ||||
|---|---|---|---|---|---|
Characteristics | 0 | 1 | 2 | ≥ 3 | Total |
| Â | (n = 2913) | (n = 1178) | (n = 312) | (n = 73) | (n = 4476) |
| Â | N (%) | N (%) | N (%) | N (%) | N (%) |
Sex | Â | Â | Â | Â | Â |
   Female | 1870 (64.2%) | 724 (61.5%) | 179 (57.4%) | 37 (50.7%) | 2810 (62.8%) |
   Male | 1043 (35.8%) | 454 (38.5%) | 133 (42.6%) | 36 (49.3%) | 1666 (37.2%) |
Age at ART initiation | Â | Â | Â | Â | Â |
   18-24.9 | 125 (4.3%) | 60 (5.1%) | 13 (4.2%) | 7 (9.6%) | 205 (4.6%) |
   25-29.9 | 427 (14.7%) | 165 (14.0%) | 50 (16.0%) | 12 (16.4%) | 654 (14.6%) |
   30-39.9 | 1390 (47.7%) | 561 (47.6%) | 149 (47.8%) | 35 (48.0%) | 2135 (47.7%) |
   40-49.9 | 714 (24.5%) | 287 (24.4%) | 79 (25.3%) | 14 (19.2%) | 1094 (24.4%) |
   ≥ 50 | 257 (8.8%) | 105 (8.9%) | 21 (6.7%) | 5 (6.9%) | 388 (8.7%) |
CD4 at ART initiation (cells/mm3) | Â | Â | Â | Â | Â |
   0-50 | 1069 (36.7%) | 433 (36.8%) | 121 (38.8%) | 26 (35.6%) | 1649 (36.8%) |
   51-100 | 680 (23.3%) | 266 (22.6%) | 62 (19.9%) | 16 (21.9%) | 1024 (22.9%) |
   101-200 | 1123 (38.6%) | 464 (39.4%) | 128 (41.0%) | 30 (41.1%) | 1745 (39.0%) |
   Missing | 41 (1.4%) | 15 (1.3%) | 1 (0.3%) | 1 (1.4%) | 58 (1.3%) |
WHO stage at ART initiation | Â | Â | Â | Â | Â |
   I/II | 1485 (51.0%) | 570 (48.4%) | 169 (54.2%) | 33 (45.2%) | 2257 (50.4%) |
   III | 1183 (40.6%) | 496 (42.1%) | 122 (39.1%) | 33 (45.2%) | 1834 (41.0%) |
   IV | 245 (8.4%) | 112 (9.5%) | 21 (6.7%) | 7 (9.6%) | 385 (8.6%) |
First-line ART regimen | Â | Â | Â | Â | Â |
   d4T/3TC/EFV | 2614 (89.7%) | 1053 (89.4%) | 280 (89.7%) | 55 (75.3%) | 4002 (89.4%) |
   d4T/3TC/NVP | 219 (7.5%) | 95 (8.1%) | 24 (7.7%) | 13 (17.8%) | 351 (7.8%) |
   AZT/3TC/EFV | 75 (2.6%) | 28 (2.4%) | 8 (2.6%) | 5 (6.9%) | 116 (2.6%) |
   AZT/3TC/NVP | 5 (0.2%) | 2 (0.2%) | 0 (0%) | 0 (0%) | 7 (0.7%) |
Outcomes by sixth month of ART | Â | Â | Â | Â | Â |
Poor CD4 response (increase <50 cells/mm3) | 509 (17.5%) | 230 (19.5%) | 60 (19.2%) | 21 (28.8%) | 820 (18.3%) |
Failure to achieve VL suppression (< 400copies/mL) | 191 (6.6%) | 80 (6.8%) | 34 (10.9%) | 11 (15.1%) | 316 (7.1%) |
Outcomes by 12 months of follow up (21 months of ART) | Â | Â | Â | Â | Â |
   Death | 71 (2.4%) | 32 (2.7%) | 6 (2.0%) | 6 (8.2%) | 115 (2.6%) |
   Loss to follow up | 174 (6.0%) | 65 (5.5%) | 27 (8.7%) | 11 (15.1%) | 277 (6.2%) |
   Transferred | 60 (2.1%) | 37 (3.1%) | 6 (2.0%) | 1 (1.0%) | 104 (2.3%) |
   Alive and in care | 2608 (89.5%) | 1044 (88.6%) | 273 (87.5%) | 55 (75.3%) | 3980 (89.0%) |
Characteristics | 0 | 1 | 2 | ≥ 3 | Total |
|---|---|---|---|---|---|
| Â | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) |
CD4 at ART initiation (cells/mm3) | 76 (29-137) | 77 (28-136) | 72 (25-136) | 82.5 (20.5-133.5) | 76 (28-136) |
CD4 nine months after ART initiation (cells/mm3) | 245 (175-334 | 238 (176-323) | 240 (177-303) | 221 (151-319) | 243 (175-328) |
Time on ART (months) | 28.4 (11.8-33.3) | 30.3 (18.0-36.3) | 30.8 (19.8-39.5) | 25.6 (15.4-40.2) | 25.6 (15.4-50.2) |
Hb at ART initiation (ug/dL) | 11.4 (10.0-12.9) | 11.5 (10.1-13.0) | 11.7 (9.9-13.1) | 11.7 (10.3-13.0) | 11.5 (10.0-12.9) |
BMI at ART initiation | 21.4 (19.0-24.4) | 21.2 (18.8-24.3) | 21.4 (19.4-24.2) | 20.6 (18.6-22.6) | 21.4 (19.0-24.3) |
Age at ART initiation | 36.1 (31.3-42.2) | 36.1 (31.4-42.1) | 35.4 (31.5-42.1) | 35.7 (29.5-40.0) | 36.1 (31.3-42.2) |
Total medical visits scheduled in first six months of ART | 4 (4-5) | 4 (3-5) | 4 (3-5) | 4 (3-5) | 4 (3-5) |
Total ARV visits scheduled in first six months of ART | 5 (4-6) | 5 (4-5) | 5 (4-5) | 4 (4-5) | 5 (4-5) |